- L'avis favorable du CHMP ouvre la voie à une commercialisation potentielle de l'obicetrapib en monothérapie et de l'association à dose fixe obicetrapib/ézétimibe en Europe - - Recommandation fondée sur les résultats positifs des essais de phase III BROADWAY, BROOKLYN et TANDEM - -...
Hence then, the article about newamsterdam pharma et le groupe menarini recoivent un avis favorable du chmp recommandant l autorisation de mise sur le marche d ubeslo obicetrapib en monotherapie et d evlarco association a dose fixe d obicetrapib et d ezetimibe was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe) )
Also on site :
- He Built His Country Music Career in Bars, Honky-Tonks and Rodeos. Now He’s Been Named Modern Country Music’s Most Influential Artist
- Judi Dench Says Panned ‘Cats’ Film Was a ‘Waste’ of Andrew Lloyd Webber’s ‘Goodwill and Talent’: ‘Oh God, I Can’t Bear It’
- 1975 Rock Anthem Beats Led Zeppelin’s ‘Stairway to Heaven’ to Become the Fan-Voted Greatest Rock Song of All Time